Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018The Tuberculosis Infection Market is Forecast to Decline Until 2018
By: Rajesh Gunnam GlobalData found that there is a lack of diagnostic capacity for the detection of TB, especially MDR-TB, which will prevent the growth of the TB drugs market. This is deemed to be a crucial barrier in preventing an effective response to the challenges of drug-resistant TB. Though recent and ongoing developments in drug therapies offer great promise for treating and curing TB, the new medicines have limited value. In developing nations where TB is the most common infection and bears 95% of the global disease burden, it is a major problem. This is because the principal diagnostic tools used for determining TB, such as microscopic examination of stained sputum and chest X-rays, do not offer accuracy in determining all forms of TB. Detection rates were observed to be low in MDR-TB patients compared to primary TB sufferers. Many poor and vulnerable people lack access to these basic diagnostic tools, which makes it too late to detect and leads them to transmit the disease to others. The limited treatment options create a substantial segment of unmet need. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ A significant unmet need lies within the TB therapeutic and prophylactic market. The TB infection market is served to an extent with current treatment options. DOTS therapy is the current gold-standard regimen for the treatment of patients newly diagnosed with TB infections. The treatment success rate with DOTS therapy is about 85%. It is highly successful but DOTS therapy has a long treatment duration and requires continuous monitoring of therapy by the health care provider. A long treatment regimen leads to poor patient compliance, which has been cited as a major obstacle, and leads to the development of MDR-TB and chronic TB. TB is unique in that even after clinical recovery, a long period of treatment is needed to prevent relapses. Most patients tend to stop taking treatment when they feel better due to a lack of knowledge, the fear of side effects or other reasons. Poor compliance leads to relapses, MDR-TB and the occurrence of chronic cases which are difficult to treat and require prolonged hospitalization in specialized centers. A significant unmet need lies within the TB prophylactic market. Bacillus Calmette Guerin (BCG) is the only vaccine approved for prophylaxis of TB. BCG protects against severe childhood disease. However, it does not prevent MDR-TB which is a major threat for spread of the disease in communities. GlobalData, the industry analysis specialist, has released its new report, “Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Tuberculosis (TB) infection market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global TB infection sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number